General selection criteria of patients for radioembolization of liver tumors: An international working group report

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 3, 2011, Pages 337-341

  Coldwell, Douglas ^a   Sangro, Bruno ^b   Wasan, Harpreet ^c   Salem, Riad ^d   Kennedy, Andrew ^e,f,g  

^a UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Wake Radiology Oncology   (United States)

^f Dep of Aerospace and Mechanical Engineering   (United States)

^g NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

eligibility; hepatic; liver; selection; yttrium 90

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; BILIRUBIN; LIVER ENZYME; PARACETAMOL; STEROID; YTTRIUM 90;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; ATELECTASIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLECYSTITIS; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM ULCER; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEVER; HUMAN; LIVER ABSCESS; LIVER CANCER; LIVER DISEASE; LIVER FUNCTION; LIVER METASTASIS; LOW DRUG DOSE; LUNG SHUNTING; MULTIMODALITY CANCER THERAPY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PATIENT SELECTION; PLEURA EFFUSION; PNEUMONIA; PORTAL VEIN THROMBOSIS; PROGNOSIS; RADIATION DOSE; RADIATION SICKNESS; RADIOEMBOLIZATION; REVIEW; STEROID THERAPY; TREATMENT RESPONSE; TUMOR ABLATION; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG SYNERGISM; EMBOLIZATION, THERAPEUTIC; HUMANS; INTERDISCIPLINARY COMMUNICATION; LIVER NEOPLASMS; MICROSPHERES; PATIENT CARE TEAM; PATIENT SELECTION; RADIATION-SENSITIZING AGENTS; YTTRIUM RADIOISOTOPES;

EID: 79958268563     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181ec61bb     Document Type: Review

References (30)

1. Gray B, van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711-1720. (Pubitemid 34105661)
2. van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/ leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78-85. (Pubitemid 39536508)
3. Lim L, Gibbs P, Yip D, et al. A prospective evaluation of treatment with selective internal radiation therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer. 2005;5:132.
4. Sharma R, van Hazel G, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25:1099-1106. (Pubitemid 46596762)
5. van Hazel GA, Pavlakis N, Goldstein D, et al. Treatment of 5-fluourouracilrefractory patients with liver metastases from colorectal cancer using yttrium 90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol. 2009;27:4089-4095.
6. Cosimelli M, Mancini R, Carpanese L, et al. Clinical safety and efficacy of 90yttrium resin microspheres alone in unresectable, heavily pre-treated colorectal liver metastases: results of a phase II trial. Poster presented at: the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2008;26(suppl). Abstract 4078.
7. King J, Quinn R, Glenn D, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008; 113:921-929.
8. Meranze SG, Bream PR, Grzeszczak E, et al. Phase II clinical trial of yttrium-90 resin microspheres for the treatment of metastatic neuroendocrine tumor. Poster presented at: Society of Interventional Radiology 32nd Annual Scientific Meeting; March 1-6, 2007; Seattle, WA. Abstract 42.
9. Kalinowski M, Dressler M, König A, et al. Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion. 2009;79:137-142.
10. Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008;19:683-690.
11. Sangro B, Bilbao JI, Boan J, et al. Radioembolisation using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:792-800. (Pubitemid 44436697)
12. Lau W, Ho S, Leung C, et al. Selective internal radiation therapy for non-resectable hepatocellular carcinoma with intra-arterial infusion of 90Yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40:583-592. (Pubitemid 28104228)
13. Lau WY, Leung WT, Ho S, et al. Treatment of inoperative hepatocellular carcinoma with intra-arterial yttrium-90 microspheres: a phase 1 and 2 study. Br J Cancer. 1994;70:994-999. (Pubitemid 24331102)
14. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000; 41:1673-1681.
15. Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of cisplatin versus 90- yttrium microspheres (Therasphere). Psychooncology. 2004;13:73-79. (Pubitemid 38247763)
16. Salem R, Lewandowski R, Roberts C, et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carci-noma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15: 335-345. (Pubitemid 38451976)
17. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71-81. (Pubitemid 351171043)
18. Kennedy AS, Dezarn W, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271-279.
19. McGrath S, Kennedy A, Dezarn W. Resin 90Y-microsphere radioembolisation is effective in controlling hepatic metastases from neuroendocrine primary cancers. Paper presented at: Emerging trends in radioembolization using microspheres: 3rd Annual Clinical Symposium; May 4 -5, 2007; Scottsdale, AZ.
20. Kennedy A, Coldwell D, Nutting C, et al. Resin 90 Y-microsphere brachytherapy for unresectable colorectal metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412-425.
21. Jakobs TF, Hoffmann RT, Dehm K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008;19:1187-1195.
22. Lim L, Gibbs P, Yip D, et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J. 2005;35:222-227. (Pubitemid 40529583)
23. Jakobs TF, Hoffmann RT, Poepperl G, et al. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using 90Yttrium resin-microspheres. Eur Radiol. 2007;17:1320-1330. (Pubitemid 46691963)
24. Gulec SA, Mesoloras G, Dezarn WA, et al. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med. 2007;5:15.
25. Szyszko T, AL-Nahhas A, Canelo R, et al. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun. 2007;28:15-20. (Pubitemid 44949683)
26. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium (REBOC). Int J Radiat Oncol Biol Phys. 2007;68:13-23. (Pubitemid 46589861)
27. Iñarrairaegui M, Thurston KG, Rodriguez M, et al. 90Y radioembolization using resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. Poster presented at: American Association for the Study of the Liver 2009; Abstract 1730.
28. Kennedy AS, Dezarn W, McNeillie P, et al. Liver tolerance to repeat 90Y-microsphere radioembolization. Poster presented at: American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract 191.
29. Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:1375-1382. (Pubitemid 47628904)
30. Salem R, Parikh P, Atassi B, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31:431-438.